RLF Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
October 19, 2024 09:06 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., October 19, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ:...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
October 18, 2024 12:00 ET
|
Glancy Prongay & Murray LLP
LOS ANGELES, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action...
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 18, 2024 08:20 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
October 17, 2024 16:05 ET
|
Aura Biosciences, Inc.
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile...
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré
October 17, 2024 12:00 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré Nantes, France,...
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
October 17, 2024 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology...
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
October 17, 2024 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 17, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...
Sarah Sheikh Joins Cerevance’s Board of Directors
October 17, 2024 08:30 ET
|
Cerevance
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric,...
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
October 17, 2024 08:15 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...